SCHEMBL20575829

SCHEMBL20575829

CC1(NC(=O)O)CCC(N(Cc2ccccc2)Cc2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 3/20 0.50
NPSR1 Q6W5P4 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ATM Q13315 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
YTHDC1 Q96MU7 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
OPRM1 P35372 1/20 0.39
OPRK1 P41145 1/20 0.39
KCNH2 Q12809 1/20 0.39
ACKR3 P25106 1/20 0.38
TSHR P16473 1/20 0.38
GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21083969 0.84 AKT1 (0.46) CCR5NPSR1KDM4EATMTDP1
SCHEMBL2144199 0.79 CCR5 (0.47) CCR5NPSR1KDM4EATMTDP1
SCHEMBL383265 0.79 CCR5 (0.47) CCR5NPSR1KDM4EATMTDP1
SCHEMBL383264 0.79 CCR5 (0.47) CCR5NPSR1KDM4EATMTDP1
SCHEMBL20576058 0.79 OPRM1 (0.55) MEN1KMT2ARAB9AOPRM1GRIN2B
SCHEMBL29856880 0.77 CCR5 (0.46) CCR5NPSR1KDM4EATMTDP1
SCHEMBL27876478 0.77 CCR5 (0.46) CCR5NPSR1KDM4EATMTDP1
SCHEMBL31629952 0.77 CCR5 (0.46) CCR5NPSR1KDM4EATMTDP1
SCHEMBL1965677 0.77 CCR5 (0.46) CCR5NPSR1KDM4EATMTDP1
SCHEMBL27987481 0.77 CCR5 (0.47) CCR5NPSR1KDM4EATMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11987584-B2 Heterobicyclic amides as inhibitors of CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-05-21 US disclosed
US-20230312586-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-10-05 US disclosed
US-20230271935-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2023-08-31 US disclosed
EP-3630748-B1 IRE1 SMALL MOLECULE INHIBITORS UNIV CORNELL (US) 2023-04-19 EP disclosed
US-11535621-B2 Heterobicyclic amides as inhibitors of CD38 RIBON THERAPEUTICS, INC. (US) 2022-12-27 US disclosed
US-20220251065-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2022-08-11 US disclosed
US-20220227730-A1 TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2022-07-21 US disclosed
US-10961218-B2 IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2021-03-30 US disclosed
US-20210032251-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-02-04 US disclosed
US-20200392106-A1 IRE1 Small Molecule Inhibitors CORNELL UNIVERSITY 2020-12-17 US disclosed
WO-2020232401-A1 COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY (US) 2020-11-19 WO disclosed
WO-2020232403-A1 TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY (US) 2020-11-19 WO disclosed
US-10745379-B2 IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2020-08-18 US disclosed
US-20190169160-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2019-06-06 US disclosed
US-20180346446-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2018-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271935-A1 IRE1 SMALL MOLECULE INHIBITORS XBP1, ERN2, ERN1 CCR5 4388/4885NPSR1 4669/4885KDM4E 1677/4885
US-20200392106-A1 IRE1 Small Molecule Inhibitors XBP1, ERN2, ERN1 CCR5 4388/4885NPSR1 4669/4885KDM4E 1677/4885
US-20210032251-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, PARP12, ENTPD2 CCR5 2119/4885NPSR1 2678/4885KDM4E 1792/4885
US-20230312586-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, PARP12, ENTPD2 CCR5 2119/4885NPSR1 2678/4885KDM4E 1792/4885
US-20220227730-A1 TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS XBP1, DDIT3, ATF4 CCR5 1838/4885NPSR1 4204/4885KDM4E 3118/4885
US-11535621-B2 Heterobicyclic amides as inhibitors of CD38 CD38, PARP12, ENTPD2 CCR5 2119/4885NPSR1 2678/4885KDM4E 1792/4885
US-10961218-B2 IRE1 small molecule inhibitors XBP1, ERN2, ERN1 CCR5 4388/4885NPSR1 4669/4885KDM4E 1677/4885
US-20220251065-A1 IRE1 SMALL MOLECULE INHIBITORS XBP1, ERN2, ERN1 CCR5 4388/4885NPSR1 4669/4885KDM4E 1677/4885
US-20180346446-A1 IRE1 SMALL MOLECULE INHIBITORS XBP1, ERN2, ERN1 CCR5 4388/4885NPSR1 4669/4885KDM4E 1677/4885
US-20190169160-A1 IRE1 SMALL MOLECULE INHIBITORS XBP1, ERN2, ERN1 CCR5 4388/4885NPSR1 4669/4885KDM4E 1677/4885
US-11987584-B2 Heterobicyclic amides as inhibitors of CD38 CD38, PARP12, ENTPD2 CCR5 2119/4885NPSR1 2678/4885KDM4E 1792/4885
US-10745379-B2 IRE1 small molecule inhibitors XBP1, ERN2, ERN1 CCR5 4388/4885NPSR1 4669/4885KDM4E 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.